AOD-9604 Mechanism of Action
Part of the full AOD-9604 guide - a growth-hormone c-terminal lipolytic fragment analogue reference compound, identity-verified with a COA on every vial.
In brief
AOD-9604 is a synthetic 16-residue analogue of the C-terminal lipolytic domain of human growth hormone (the hGH 176-191 fragment) carrying an added N-terminal tyrosine. In adipocyte and rodent laboratory models it is studied as a tool that separates the metabolic signaling of the parent hormone's C-terminal fragment from classical growth-hormone-receptor activity. All characterization below is in-vitro and preclinical receptor- and metabolic-signaling work; no therapeutic, weight, or human claim is implied.
The detail
A closer look
01
Reproducing fragment signaling without GH-receptor engagement
The defining feature reported for AOD-9604 in cell and rodent models is that it reproduces the lipolytic (fat-mobilizing) signaling associated with the parent hormone's C-terminal fragment without engaging the growth-hormone receptor. Because it is modeled on residues 176-191 of human growth hormone rather than the full hormone, the molecule lacks the structural surfaces needed for classical GH-receptor agonism. In the framework described for this peptide, the lipolytic readout in fat-cell models is therefore treated as a property of the C-terminal domain itself, studied in isolation from whole-hormone receptor binding.
02
Association with beta-3 adrenergic signaling
Mechanistic work cited for AOD-9604 associates its lipolytic readout in fat-cell models with up-regulation of beta-3 adrenergic receptor (beta3-AR) signaling, rather than direct growth-hormone-receptor agonism. The beta3-AR pathway is the adrenergic axis classically linked to lipolytic signaling in adipocytes, and the entry's source literature frames AOD-9604's metabolic effect through this receptor system. The Heffernan et al. (2001) study cited here specifically examined the lipolytic fragment in both obese-mouse and beta(3)-AR knockout backgrounds, which is the experimental design that ties the readout to the beta3-AR axis in this dataset.
03
Decoupling lipolytic signaling from the IGF-1 / GH axis
A central reason the peptide is studied is that, in these models, it produces a lipolytic signaling readout without stimulating IGF-1 production. This is the property that separates the fragment's metabolic signaling from the downstream IGF-1 output of classical GH-receptor activation. The keyFacts note records this directly as 'lipolytic without IGF-1 stimulation in models.' For researchers, that decoupling is the experimental point of interest: it allows the C-terminal lipolytic domain to be examined as a metabolic-signaling element distinct from the somatotropic (growth-promoting, IGF-1-driven) arm of growth-hormone biology.
04
Conformational constraint from the intramolecular disulfide
The sequence contains two cysteine residues (at positions 7 and 14 of the 16-residue chain). These two cysteines form an intramolecular disulfide bond that constrains the fragment's conformation. In structure-activity terms, this disulfide locks the peptide into a defined three-dimensional shape rather than leaving it as a freely flexible chain, which is the structural basis for presenting the lipolytic domain to its signaling targets in a reproducible conformation. This conformational constraint is the molecular-structure detail most relevant to how the fragment's signaling surface is maintained in laboratory studies.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. AOD-9604 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.